KRAS Tests – In Vitro Diagnostics Market Analysis and Forecast Model
- Pages: 0
- Published: May 2019
- Report Code: GDME365MM
Globally, lung cancer is the second most common cancer in men and the third most common cancer in women. There are two main types of lung cancer; small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), with NSCLC accounting for approximately 80-90% of all lung cancer cases. The 5-year survival rate for patients with stage IV disease is less than 5% as majority of patients present with the advanced or metastatic disease at diagnosis. Kirsten rat sarcoma (KRAS) is a downstream signaling molecule in the EGFR cellular pathway with roles in cell growth and proliferation. It is commonly mutated in both CRC (39%) and NSCLC (25%) with the most frequent mutations in codons 12 and 13 causing over-activation of KRAS, which results in excessive cellular proliferation and tumor growth. There are no clinically approved therapies that target KRAS. However, its mutational status serves as an indication for response to approved anti-EGFR receptor antibodies in CRC and Tyrosine Kinase Inhibitors (TKIs) in NSCLC. Patients that have mutations in KRAS will not benefit from these anti-EGFR therapies. Therefore, major organizations such as the National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO) and others throughout Asia suggest that all late-stage metastatic CRC (stage IV) patients be tested for KRAS mutations when EGFR therapy is considered. However, such a strong consensus has not yet been reached for KRAS testing in late stages of NSCLC.
Who should buy this report?
This Market Model gives important, expert insight you won’t find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for:
• CMO executives who must have deep understanding of the KRAS Tests marketplace to make strategic planning and investment decisions.
• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.
Currently marketed KRAS Tests and evolving competitive landscape:
• Insightful review of the key industry trends.
• Annualized total KRAS Tests market revenue by segment and market outlooks from 2015–2028.
• Granular data on total procedures, units, average selling prices and market values by segment.
Reasons to buy
The model will enable you to:
• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving KRAS Tests market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the KRAS Tests market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Track device sales in the global and country-specific KRAS Tests market from 2015-2028.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
F. Hoffmann-La Roche Ltd (Roche Diagnostics International Ltd)
Agilent Technologies Inc
Thermo Fisher Scientific Inc
Agena Bioscience Inc
Takara Bio Inc
New England Biolabs Inc
Amoy Diagnostics Co Ltd
Biocartis Group NV